poisar

Stock

NextCure, Inc. NXTC

$6.82+1.56%

Overview

NXTC market data

Business OverviewA provider-written description of this company or fund, with its source and observation date.

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Official website

Source
massive
Observed
Cadence
Reference data reviewed periodically
Status
fresh

Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.

NXTC price chart · 1M
O
7.25
H
7.25
L
6.79
C
6.82
Vol
441.00

Daily history from May 9, 2019

Source
US equities market feed
Observed
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.

Open
$7.25
Previous Close
$6.71
Day High
$7.25
Day Low
$6.79
52 Week High
$15.61
52 Week Low
$1.56
7 Day Return
+14.54%
30 Day Return
+20.51%
90 Day Return
+1.64%
1 Year Return
-31.58%
Daily Notional Volume
$3K
Latest daily bar volume multiplied by its closing price.

Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.

Provider-backed
P/E (TTM)
—
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
—
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$2.00
Diluted earnings per share over the trailing twelve months.
Beta
1.27
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
—
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-65.2%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$1.55 – $15.74
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
—
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $32.3M · P/B 1.42 · P/S 1.18.

Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.

6 captured

Decision & ScoreThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern EvidenceThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer RankingThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock